Foghorn Therapeutics Inc
$ 4.59
-4.18%
10 Apr - close price
- Market Cap 281,174,000 USD
- Current Price $ 4.59
- High / Low $ 4.78 / 4.53
- Stock P/E N/A
- Book Value -1.92
- EPS -1.18
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -4.70 %
- 52 Week High 6.95
- 52 Week Low 3.26
About
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$11.44
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-05 | 2025-08-05 | 2025-05-05 | 2025-03-05 | 2024-10-31 | 2024-08-08 | 2024-05-06 | 2024-03-07 | 2023-11-02 | 2023-08-04 | 2023-05-08 |
| Reported EPS | -0.3654 | -0.25 | -0.28 | -0.3 | -0.3 | -0.31 | -0.45 | -0.59 | -0.57 | -0.34 | -0.7 | -0.73 |
| Estimated EPS | -0.2589 | -0.3333 | -0.3514 | -0.29 | -0.285 | -0.44 | -0.65 | -0.63 | -0.76 | -0.75 | -0.73 | -0.72 |
| Surprise | -0.1065 | 0.0833 | 0.0714 | -0.01 | -0.015 | 0.13 | 0.2 | 0.04 | 0.19 | 0.41 | 0.03 | -0.01 |
| Surprise Percentage | -41.1356% | 24.9925% | 20.3187% | -3.4483% | -5.2632% | 29.5455% | 30.7692% | 6.3492% | 25% | 54.6667% | 4.1096% | -1.3889% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FHTX
2026-04-10 02:39:00
Foghorn Therapeutics announced it will present new preclinical data for its selective SMARCA2 inhibitor FHD-909, as well as for its selective CBP, EP300, and ARID1B degrader programs at the 2026 AACR Annual Meeting. The data highlights potential expansion opportunities for FHD-909 in SMARCA4-mutant lung cancer and promising results for its degrader programs in ER+ breast cancer, hematological malignancies, and ARID1A-mutant tumors. These presentations underscore Foghorn's pipeline of differentiated therapies targeting abnormal gene expression.
2026-04-09 11:09:35
Foghorn Therapeutics announced new preclinical data for its oncology programs, which will be presented at AACR2026. The company highlighted the differentiated profiles of its therapeutic candidates, underscoring ongoing progress in innovative cancer research. Foghorn Therapeutics aims to demonstrate the potential impact of these programs as they move towards future clinical development.
2026-04-09 11:09:35
Foghorn Therapeutics announced it will present new preclinical data for its selective SMARCA2 inhibitor FHD-909 and other degrader programs at the 2026 AACR Annual Meeting. The data for FHD-909 will highlight potential expansion opportunities in combination with an anti-PD-1 antibody for SMARCA4-mutant lung cancer. Additional presentations will cover progress on selective CBP, EP300, and ARID1B degrader programs, emphasizing their potential in various cancers.
2026-04-09 11:09:35
Foghorn Therapeutics (NASDAQ: FHTX) is set to present new preclinical data at the 2026 AACR Annual Meeting from April 17–22 in San Diego. The company will showcase data for its selective SMARCA2 inhibitor FHD-909, with potential in SMARCA4-mutant lung cancer, and various degrader programs including CBP (FHT-171), EP300, and ARID1B, targeting ER+ breast cancer and hematologic malignancies. These presentations highlight Foghorn's pipeline of early-stage oncology work, emphasizing its proprietary Gene Traffic Control® platform in addressing serious diseases by correcting abnormal gene expression.
2026-04-09 11:09:35
Foghorn Therapeutics (NASDAQ:FHTX) announced it will present preclinical data for its cancer treatments, FHD-909 and FHT-171, at the 2026 American Association for Cancer Research Annual Meeting. The company will also deliver oral and poster presentations on its various degrader programs. Despite facing continued losses in 2026, analysts see significant upside potential for FHTX stock.
2026-04-05 08:39:32
Foghorn Therapeutics Inc. (NASDAQ:FHTX) has received a consensus "Moderate Buy" rating from ten brokerages, with an average 1-year price target of $11.125. Despite recent Q1 earnings missing analyst estimates, the clinical-stage biotech company is advancing its lead epigenetic cancer therapy, FHD-286, in Phase 1 trials. Hedge funds and institutional investors have been adjusting their stakes in FHTX, which currently trades around $4.93 with a market cap of $289.39 million.
